Enhancing glioma care with advanced imaging: T2-FLAIR mismatch as a predictive biomarker in IDH-mutant astrocytoma

The study highlights that diffuse glioma, a prevalent type of brain tumor, affect approximately 100,000 individuals worldwide each year. IDH-mutant astrocytoma and oligodendrogliomas typically have a more favorable prognosis compared to IDH-wildtype glioblastomas. However, many IDH-mutant astrocytom...

Full description

Saved in:
Bibliographic Details
Published in:Neurosurgical review 2024-08, Vol.47 (1), p.512, Article 512
Main Authors: Nadeem, Manal, Shahzad, Umer Bin, Tahir, Nawal, Areej, Ayesha
Format: Article
Language:English
Subjects:
Astrocytoma - diagnostic imaging
Astrocytoma - genetics
Biomarkers, Tumor - genetics
Brain Neoplasms - diagnostic imaging
Brain Neoplasms - genetics
Correspondence
Glioma - diagnostic imaging
Glioma - genetics
Humans
Isocitrate Dehydrogenase - genetics
Magnetic Resonance Imaging - methods
Medicine
Medicine & Public Health
Mutation
Neurosurgery
Prognosis
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The study highlights that diffuse glioma, a prevalent type of brain tumor, affect approximately 100,000 individuals worldwide each year. IDH-mutant astrocytoma and oligodendrogliomas typically have a more favorable prognosis compared to IDH-wildtype glioblastomas. However, many IDH-mutant astrocytoma has the potential to progress to grade 4 glioblastomas, leading to a less favorable prognosis. In a recent investigation, Shumpei Onishi et al. examined the T2-FLAIR mismatch sign as a possible imaging biomarker for assessing CDKN2A status in non-enhancing IDH-mutant astrocytoma. The findings indicate that the T2-FLAIR mismatch sign is linked to CDKN2A-intact astrocytoma, providing a valuable tool for diagnostic and prognostic purposes. Additionally, the use of Indocyanine Green (ICG) for real-time visualization during neurosurgical procedures demonstrates potential, though it may have limitations in specificity. While these advancements offer promise in glioma management, there remains a critical need for larger, standardized studies to validate these findings and further improve treatment outcomes.
ISSN:1437-2320
1437-2320
DOI:10.1007/s10143-024-02748-8